Disease Natural History and Biomarkers of SPG3A, SPG4A, and SPG31
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02859428|
Recruitment Status : Terminated (Investigator left NIH)
First Posted : August 9, 2016
Last Update Posted : October 20, 2020
Hereditary spastic paraplegia (HSP) usually progresses slowly. Researchers want to learn more about how its symptoms change over time. They want to look for changes in the blood and cells of people with the most common forms of HSP that might allow them to better understand the disease.
To learn more about common forms of hereditary spastic paraplegia and find out how it progresses over time.
People age 7 and older with SPG3A, SPG4A, or SPG31
Participants will have 1 two-hour visit each year for up to 5 years.
At 1 visit, adult participants may have a skin biopsy. An area of skin will be numbed then a tool will remove a small piece of skin.
At all visits, all participants will have a physical exam and blood drawn.
At all visits, participants will do a few tasks like walking quickly and climbing stairs.
Participants can give permission for their skin cells, DNA samples, and data to be used in other studies. The samples and data will have no identifying information.
|Condition or disease|
|Hereditary Spastic Paraplegia|
The Neurogenetics Branch (NGB) within the National Institute of Neurological Disorders and Stroke (NINDS) is conducting a study to evaluate patients with hereditary spastic paraplegia types 3A, 4 and 31. The objective of this study is to understand disease progression in these closely related forms of hereditary spastic paraplegia using validated rating scales such as the Spastic Paraplegia Rating Scale (SPRS), and Medical Outcomes Study Questionnaire Short Form 36 Health Survey (SF-36). We also hope to develop biomarkers that could be used in future treatment trials from human serum and by utilizing transcranial magnetic stimulation (TMS) to determine central motor conduction times and resting motor thresholds.
The primary objective of this protocol is to study the natural history of the most common forms of autosomal dominant hereditary spastic paraplegia. The information obtained from validated rating scales (SPRS and SF-36), TMS, and serum biomarkers, will allow for the development of treatment trials. In some cases, blood or other biologic samples (including skin biopsies) will be obtained for future laboratory studies.
The number of participants to be enrolled will be set to 300.
This is an observational study of autosomal dominant forms of hereditary spastic paraplegia progression, pathophysiology, and biomarkers.
In this study we will track disease progression using the Spastic Paraplegia Rating Scale (SPRS) and SF-36. Also, we will measure levels of plasma lipids, insulin, leptin, and of certain micro RNAs to investigate their utility as biomarkers. We will utilize TMS (combined with nerve conducting studies) to assess central motor conduction times (CMCT) and resting motor thresholds (RMT).
|Study Type :||Observational|
|Actual Enrollment :||51 participants|
|Official Title:||Disease Natural History and Biomarkers of SPG3A, SPG4 and SPG31|
|Actual Study Start Date :||November 18, 2016|
|Actual Primary Completion Date :||October 16, 2020|
|Actual Study Completion Date :||October 16, 2020|
Patients with hereditary spastic paraplegia (HSP)
Patients with hereditary spastic paraplegia types 3A, 4 and 31.
- Spastic Paraplegia Rating Scale (SPRS) [ Time Frame: Once a year for five years ]Disease progression as measured by the SPRS and SF-36 scales.
- SF-36 [ Time Frame: Once a year for five years ]Disease progression as measured by the SPRS and SF-36 scales.
- Cortical silent period [ Time Frame: Once a year for five years ]Cortical silent period
- CMCT, resting motor thresholds, MEP amplitude and MEP latency [ Time Frame: Once a year for five years ]CMCT, resting motor thresholds, MEP amplitude and MEP latency
- miRNA relative quantity. [ Time Frame: Once a year for five years ]miRNA relative quantity.
- Fasting Triglycerides, total Cholesterol, HDL and LDL, Leptin, Insulin levels. [ Time Frame: Once a year for five years ]Fasting Triglycerides, total Cholesterol, HDL and LDL, Leptin, Insulin levels.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02859428
|United States, Maryland|
|National Institutes of Health Clinical Center|
|Bethesda, Maryland, United States, 20892|
|Principal Investigator:||Craig D Blackstone, M.D.||National Institute of Neurological Disorders and Stroke (NINDS)|